Welcome to our dedicated page for Icecure Medical Ltd. news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on Icecure Medical Ltd. stock.
IceCure Medical Ltd. (Nasdaq: ICCM) is a commercial-stage medical device company that develops liquid-nitrogen-based cryoablation systems for minimally invasive destruction of benign and cancerous tumors. News about IceCure often centers on its flagship ProSense® Cryoablation System and its role as an option to surgical tumor removal, particularly in breast cancer and other oncology indications.
Investors and clinicians following ICCM news can expect updates on regulatory milestones, commercial expansion, and clinical data. Recent company communications highlight U.S. Food and Drug Administration (FDA) marketing authorization for ProSense® for the local treatment of low-risk breast cancer with adjuvant endocrine therapy in women aged 70 and above, including those not suitable for surgery. News items also cover regulatory approvals in markets such as Switzerland and Israel, as well as patent developments for next-generation systems like XSense™ and cryogen flow control technologies.
IceCure’s news flow frequently includes coverage of independent clinical studies and conference presentations. ProSense® has been featured in abstracts and talks at major meetings such as the Radiological Society of North America (RSNA) Annual Meeting, the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting, and the European Society of Breast Imaging (EUSOBI) Congress. These reports describe clinical experience in breast cancer, lung cancer, musculoskeletal tumors, kidney lesions, and abdominal wall endometriosis.
Company updates may also address financial and operational results, commercial traction in regions including North America and Europe, and interactions with Nasdaq listing requirements. For users tracking ICCM, this news page provides a centralized view of press releases, clinical milestones, regulatory developments, and commercialization updates related to IceCure’s cryoablation platforms.
IceCure (Nasdaq: ICCM) priced a registered direct offering of 8,000,000 ordinary shares at $0.50 per share for gross proceeds of approximately $4.0 million. In a concurrent private placement the company will issue Series B and Series C warrants to purchase up to 8,000,000 shares each, exercisable at $0.55.
The Series B warrants expire five years after issuance; Series C warrants expire one year after issuance. Closing is expected on or about March 27, 2026. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners is sole placement agent.
IceCure (Nasdaq: ICCM) reported positive top-line 5-year results from the ICESECRET trial of ProSense cryoablation for small renal masses (SRMs). At a median follow-up of four years, 83.9% of patients were recurrence-free; a subgroup with tumors ≤3 cm and no prior kidney cancer showed 89.4% recurrence-free.
The single-arm study enrolled 114 patients (138 lesions); 112 were evaluated. Detailed data will be presented at ECIO 2026 in Basel.
IceCure (NASDAQ: ICCM) appointed Meir Peleg as Chief Financial Officer, effective May 17, 2026, and plans to appoint Richard E. Fine, MD, as Medical Director for breast indications in Q2 2026. The company cites strong commercial momentum for ProSense® after FDA clearance in low‑risk breast cancer and an ASBrS recommendation.
IceCure initiated a search for a Chief Technology Officer and said VP of R&D Naum Muchnik will depart effective April 12, 2026. IceCure noted the FDA‑approved ChoICE post‑marketing study for ProSense®.
IceCure (Nasdaq: ICCM) reported record fourth-quarter sales of $1.3M and full-year 2025 revenue of $3.379M, driven by U.S. FDA clearance for ProSense® in low-risk breast cancer, new ASBrS guideline support, and expansion plans including a 30-site ChoICE post-marketing study.
Financials show gross profit $1.226M and narrowed net loss of $15.057M; cash and equivalents rose to $8.897M. Health Canada expansion application pending; patient enrollment for ChoICE expected H2 2026.
IceCure (Nasdaq: ICCM) announced that the U.S. FDA approved the study design for the ChoICE Trial Post-Market Study of ProSense® cryoablation for low-risk breast cancer.
Key points: FDA marketing authorization was granted in October 2025 for patients ≥70 with tumors ≤1.5 cm; enrollment is expected to start in H2 2026, targeting ~400 patients across 30 U.S. sites within 36 months, with at least 80 patients in year one. The Study will use IceCure-exclusive cryoprobes and sites may treat non-study patients commercially; procedures are eligible for CPT Category III reimbursement (about $4,000 facility fee).
IceCure Medical (Nasdaq: ICCM) will report full year financial and operating results for the twelve months ended December 31, 2025 before the Nasdaq opens on March 17, 2026. A conference call and live webcast to discuss results and corporate developments will follow at 11:00 a.m. EDT on the same day.
Conference call dial-ins and a live webcast link are provided; a recording will be available on the company's investor website.
IceCure Medical (Nasdaq: ICCM) said the American Society of Breast Surgeons' 2026 Resource Guide now recommends cryoablation as an option for selected biologically low-risk early-stage breast cancer patients. The update follows FDA marketing clearance for ProSense® in October 2025 and cites clinical evidence and multidisciplinary care principles.
The guide affirms cryoablation for fibroadenomas and recognizes ProSense® as the first FDA-cleared device for low-risk breast cancer, potentially accelerating commercial adoption, aided by an established CPT III reimbursement code and an estimated U.S. addressable population of ~200,000 women annually.
IceCure Medical (Nasdaq: ICCM) announced publication in PLOS One of an independent study showing ProSense® cryoablation is safe and effective for breast fibroadenomas.
The study reported a median volume reduction of 80.6% at ~6 months and 92.9% at one year, evaluated larger lesions using up to three cryoprobe relocations, and notes ProSense® has FDA clearance for fibroadenomas.
IceCure Medical (Nasdaq: ICCM) completed five-year follow up for its ICESECRET kidney cancer trial of ProSense, covering 114 patients and 138 lesions.
Interim three-year data from 111 patients showed an 88.7% recurrence-free rate. ProSense is approved for kidney tumors in the U.S., Europe and other countries; final analysis is expected in Q2 2026.
IceCure (NASDAQ: ICCM) announced that Thomas Hospital of Fairhope, part of Infirmary Health, purchased and installed the ProSense® cryoablation system, becoming the first hospital in Alabama to offer breast cancer cryoablation. Procedures are scheduled to begin in the coming weeks, funded by the Thomas Hospital Foundation. The move follows the October 2025 FDA clearance for local treatment of low-risk breast cancer and growing clinical interest.